News
BSX
73.21
-0.08%
-0.06
Validea Detailed Fundamental Analysis - BSX
NASDAQ · 10h ago
3 Medical Products Stocks Set to Beat This Earnings Season
NASDAQ · 10h ago
Boston Scientific Is Maintained at Overweight by Barclays
Dow Jones · 12h ago
Boston Scientific Price Target Raised to $78.00/Share From $70.00 by Barclays
Dow Jones · 12h ago
Barclays Maintains Overweight on Boston Scientific, Raises Price Target to $78
Benzinga · 12h ago
Top 4 Health Care Stocks That May Plunge This Month
Four stocks in the health care sector are overbought as of April 26, 2024. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when prices fall. Fusion Pharmaceuticals Inc. Is one of the four stocks with a RSI value above 70.
Benzinga · 14h ago
BOSTON SCIENTIFIC CORP <BSX.N>: BARCLAYS RAISES TARGET PRICE TO $78 FROM $70
Reuters · 14h ago
Barclays Reaffirms Their Buy Rating on Boston Scientific (BSX)
TipRanks · 17h ago
Boston Scientific Is Maintained at Buy by Citigroup
Dow Jones · 1d ago
Boston Scientific Price Target Raised to $85.00/Share From $79.00 by Citigroup
Dow Jones · 1d ago
Citigroup Maintains Buy on Boston Scientific, Raises Price Target to $85
Benzinga · 1d ago
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength
Edwards Lifesciences first-quarter profit beats estimates on heart devices strength. Company expects annual sales growth to be at the higher end of its 8% to 10% forecast. Sales of Edwards' artificial heart valves rose 6% to $1 billion in the first quarter.
Reuters · 1d ago
(BSX) - Analyzing Boston Scientific's Short Interest
Boston Scientific's short percent of float has risen 8.97% since its last report. The company has 12.43 million shares sold short, which is 0.85% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 1d ago
Boston Scientific Is Maintained at Hold by Deutsche Bank
Dow Jones · 1d ago
Boston Scientific Price Target Raised to $73.00/Share From $63.00 by Deutsche Bank
Dow Jones · 1d ago
Upcoming Deadline to Share in Boston Scientific Corporation (BSX) Class Action Settlement
TipRanks · 1d ago
Deutsche Bank Maintains Hold on Boston Scientific, Raises Price Target to $73
Benzinga · 1d ago
Boston Scientific Is Maintained at Overweight by JP Morgan
Dow Jones · 1d ago
Boston Scientific Price Target Raised to $82.00/Share From $72.00 by JP Morgan
Dow Jones · 1d ago
JP Morgan Maintains Overweight on Boston Scientific, Raises Price Target to $82
Benzinga · 1d ago
More
Webull provides a variety of real-time BSX stock news. You can receive the latest news about Boston Scien Cp through multiple platforms. This information may help you make smarter investment decisions.
About BSX
Boston Scientific Corporation is a global developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company’s segments include MedSurg and Cardiovascular. The MedSurg segment includes Endoscopy, Urology and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a broad range of gastrointestinal (GI) and pulmonary conditions with less invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. The Cardiovascular segment includes Cardiology and Peripheral Interventions. The Company's Interventional Cardiology Therapies business develops and manufactures technologies for diagnosing and treating coronary artery disease and aortic valve conditions.